Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 17/20 | 0.39 |
| ▸ | AKT1 | P31749 | 6/20 | 0.36 |
| ▸ | AKT2 | P31751 | 3/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4928920 | 0.86 | RPS6KB1 (0.36) | RPS6KB1AKT1AKT2RPS6KA3 | |
| Trifluoroacetic Acid SCHEMBL4930137 | 0.84 | RPS6KB1 (0.52) | RPS6KB1AKT1AKT2RPS6KA3HTR1A | |
| SCHEMBL1792704 | 0.80 | RPS6KB1 (0.59) | RPS6KB1AKT1AKT2RPS6KA3 | |
| SCHEMBL4923098 | 0.79 | RPS6KB1 (0.37) | RPS6KB1AKT1AKT2RPS6KA3 | |
| SCHEMBL4923245 | 0.79 | RPS6KB1 (0.48) | RPS6KB1AKT1AKT2RPS6KA3 | |
| SCHEMBL4931519 | 0.78 | RPS6KB1 (0.48) | RPS6KB1AKT1AKT2RPS6KA3 | |
| SCHEMBL5577231 | 0.78 | RPS6KB1 (0.43) | RPS6KB1AKT1AKT2RPS6KA3 | |
| SCHEMBL4932473 | 0.78 | RPS6KB1 (0.41) | RPS6KB1AKT1AKT2RPS6KA3 | |
| SCHEMBL2293886 | 0.77 | RPS6KB1 (0.41) | RPS6KB1AKT1AKT2RPS6KA3HTR1A | |
| SCHEMBL4926368 | 0.77 | RPS6KB1 (0.45) | RPS6KB1AKT1AKT2RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | RPS6KB1 13/4885AKT1 6/4885AKT2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.